pSivida Corp

Press Releases

All Releases
View Summary pSivida Announces Successful Completion of Two Preclinical Studies of Durasert™ Sustained-Release Insert Delivering Repurposed Cancer Drug to Treat Wet AMD
Jul 5, 2016
PDF 18.3 KB Add to Briefcase
View Summary pSivida Corp. Provides Company Update and Reports Third Quarter FY 2016 Results
May 5, 2016
PDF 34.6 KB Add to Briefcase
View Summary pSivida CEO to Present at 2016 International Symposium of Ocular Pharmacology and Therapeutics
May 4, 2016
PDF 16.4 KB Add to Briefcase
View Summary pSivida's Medidur for Posterior Uveitis Granted Orphan Drug Designation in Europe
May 2, 2016
PDF 17.4 KB Add to Briefcase
View Summary pSivida Corp. Announces Third Quarter Fiscal Year 2016 Financial Results Release Date and Conference Call Information
Apr 27, 2016
PDF 16.4 KB Add to Briefcase
View Summary pSivida to Present at the Sidoti Spring 2016 Emerging Growth Convention
Mar 24, 2016
PDF 16.4 KB Add to Briefcase
View Summary Additional Favorable Six-Month Safety Results for pSivida's Medidur™ for Posterior Uveitis
Mar 15, 2016
PDF 20.0 KB Add to Briefcase
View Summary pSivida Corp. Provides Company Update and Reports Second Quarter FY 2016 Results
Feb 8, 2016
PDF 35.3 KB Add to Briefcase
View Summary pSivida Corp Announces Second Quarter Fiscal Year 2016 Financial Results Release Date and Conference Call Information
Feb 1, 2016
PDF 16.5 KB Add to Briefcase
View Summary pSivida CEO to Present at 18th Annual Bio CEO & Investor Conference February 9
Jan 28, 2016
PDF 17.3 KB Add to Briefcase
View Summary pSivida Closes $17.8 Million Offering
Jan 13, 2016
PDF 14.7 KB Add to Briefcase
View Summary pSivida Announces Pricing of $16 Million Public Offering of Common Stock
Jan 7, 2016
PDF 14.3 KB Add to Briefcase
View Summary pSivida Announces Proposed Public Offering of Common Stock
Jan 6, 2016
PDF 14.8 KB Add to Briefcase
View Summary pSivida Plans Medidur™ EU Marketing Approval Application Based on Single Phase 3 Clinical Trial
Dec 28, 2015
PDF 20.6 KB Add to Briefcase
View Summary pSivida's Medidur™ Meets Primary Efficacy Endpoint in Phase 3 Trial: High Statistical Significance in Prevention of Recurrence of Posterior Uveitis (p Less Than 0.00000001)
Dec 22, 2015
PDF 27.6 KB Add to Briefcase
View Summary pSivida Corp. Provides Company Update and Reports First Quarter FY 2016 Results
Nov 5, 2015
PDF 32.6 KB Add to Briefcase
View Summary pSivida Corp Announces First Quarter FY 2016 Financial Results Release Date and Conference Call Information
Oct 30, 2015
PDF 14.4 KB Add to Briefcase
View Summary pSivida Announces NDA for Medidur™ Now Planned Using Six-Month Efficacy Data from Both Phase III Trials; FDA Concurs
Sep 28, 2015
PDF 16.7 KB Add to Briefcase
View Summary pSivida CEO to Present at Ladenburg Thalmann 2015 Healthcare Conference September 29, 2015
Sep 14, 2015
PDF 16.2 KB Add to Briefcase
View Summary pSivida Corp. Provides Company Update and Reports Fourth Quarter and FY 2015 Results
Sep 9, 2015
PDF 32.7 KB Add to Briefcase
Showing 41-60 of 286 Page: 1 2 3 4 5 6 7 ... 15  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase

Search Investor Relations

pSivida